Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Want to see AU:AVE full AI Analyst Report?
Top Page
Avecho Biotechnology Limited
(Sydney:AVE)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.01
▲(20.00% Upside)
Action:Reiterated
Date:05/26/26
The score is primarily held back by persistent net losses and a shrinking equity base, despite improved 2025 revenue momentum and a swing to positive operating/free cash flow. Technicals add caution due to an extremely overbought RSI and a slightly negative MACD, while valuation is weak because the company is loss-making and provides no dividend yield.
Positive Factors
Revenue Momentum
Accelerating revenue in 2025 indicates improving product adoption and market traction for Avecho's TPM platform. Over the next 2–6 months sustained top-line momentum can improve operating leverage, support investment in commercialization, and reduce near-term reliance on external funding if maintained.
Negative Factors
Persistent Losses & Shrinking Equity
Ongoing sizable operating and net losses that have eroded equity create a structural risk to shareholder value and financing flexibility. If losses persist, management may need to raise capital or dilute shareholders, impairing the firm's ability to execute long-term commercial strategies without sustained profit improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Accelerating revenue in 2025 indicates improving product adoption and market traction for Avecho's TPM platform. Over the next 2–6 months sustained top-line momentum can improve operating leverage, support investment in commercialization, and reduce near-term reliance on external funding if maintained.
Read all positive factors
Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$49.80M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth9.28%
EPS Growth-40.00%
CountryAU
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,830,448,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avecho Biotechnology Limited Business Overview & Revenue Model
Company Description
Avecho Biotechnology Limited, an Australian biotech firm established in Clayton in 1992 (originally known as Phosphagenics until May 2019), specializes in the creation, manufacturing, and distribution of products leveraging its proprietary Targete...
How the Company Makes Money
Avecho’s monetisation model is primarily based on commercialising its proprietary TPM drug-delivery technology and any products formulated using it. Revenue can be generated through (1) licensing TPM to partners for use in their products, which ty...
Avecho Biotechnology Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.24M | 1.13M | 473.55K | 1.13M | 793.60K |
| Gross Profit | 751.29K | 671.93K | -43.80K | 793.12K | 507.94K |
| EBITDA | -5.87M | -2.92M | -3.24M | -2.11M | -2.98M |
| Net Income | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M |
Balance Sheet | |||||
| Total Assets | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Cash, Cash Equivalents and Short-Term Investments | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total Debt | 14.47K | 1.08M | 175.15K | 246.07K | 93.91K |
| Total Liabilities | 5.55M | 1.73M | 941.54K | 920.66K | 709.36K |
| Stockholders Equity | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
Cash Flow | |||||
| Free Cash Flow | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M |
| Operating Cash Flow | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M |
| Investing Cash Flow | 0.00 | -15.73K | 0.00 | -53.12K | -202.82K |
| Financing Cash Flow | 1.19M | 854.59K | 7.22M | -78.22K | 4.69M |
Avecho Biotechnology Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$11.43M | -1.95 | -43.95% | ― | 14.30% | 41.93% | |
47 Neutral | AU$23.35M | -4.26 | 2509.60% | ― | ― | -137.97% | |
45 Neutral | AU$49.80M | -14.47 | -370.40% | ― | 9.28% | -40.00% | |
45 Neutral | AU$4.05M | -0.15 | 2844.96% | ― | ― | 62.07% | |
45 Neutral | AU$17.08M | -2.96 | -91.88% | ― | -55.21% | 36.36% | |
42 Neutral | AU$21.25M | -18.31 | -49.25% | ― | ― | 25.00% |
* Healthcare Sector Average
AU:AVE
Avecho Biotechnology Limited
0.01
<0.01
30.00%
AU:1AI
Living Cell Technologies
0.01
<0.01
10.00%
AU:IMC
Immuron Limited
0.03
-0.03
-49.23%
AU:NOX
Noxopharm Ltd.
0.08
0.01
16.92%
AU:CHM
Chimeric Therapeutics Ltd.
0.07
-0.10
-58.24%
AU:MEM
Memphasys Ltd
―
―
―
Avecho Biotechnology Limited Corporate Events
Avecho secures strong shareholder backing at 2026 AGM as all put resolutions pass
May 26, 2026
Avecho Biotechnology reported the voting outcomes of its 2026 Annual General Meeting, confirming that all resolutions put to shareholders, including the adoption of the remuneration report and ratifications of prior share and option issues, were c...
Avecho strengthens balance sheet as Phase III insomnia trial nears key read-out
May 26, 2026
Avecho Biotechnology used its 2026 AGM to highlight steady execution of its strategy following the licensing of Australian commercial rights for its TPM‑enhanced cannabidiol soft-gel capsule to Sandoz. The company reported a markedly stronge...
Avecho Director Resigns as CBD Insomnia Program Enters Critical Phase
May 25, 2026
Avecho Biotechnology has announced the resignation of non-executive director Matthew McNamara, effective 25 May 2026, after nearly seven years on the board, prompting the withdrawal of his re-election resolution from the upcoming AGM but leaving t...
Avecho readies Phase III interim analysis on CBD insomnia capsule amid surging sleep market
May 25, 2026
Avecho Biotechnology is advancing its TPM-based drug delivery platform, focusing on human and animal health applications that enhance oral, dermal and transdermal absorption, with its main product a cannabidiol soft-gel capsule aimed at improving ...
Avecho Secures A$1.98m R&D Tax Refund to Advance CBD Insomnia Program
May 22, 2026
Avecho Biotechnology has received A$1.98 million under the Australian Government’s RD Tax Incentive Scheme for the year ended 31 December 2025, underscoring its ongoing investment in differentiated cannabinoid formulations aimed at pharmaceu...
Avecho hits key milestone in Phase III CBD insomnia trial ahead of interim data
May 21, 2026
Avecho Biotechnology has completed the treatment phase for the 244 patients needed for an interim analysis of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia. The study, designed to support Australian regulatory regi...
Avecho director reshapes indirect stake as options exercised and lapse
May 13, 2026
Avecho Biotechnology has reported a change in the indirect holdings of director Gregory Collier, primarily through his interests in Beacon Super Fund Pty Ltd and Barwon Biotechnology Pty Ltd. The disclosure details the restructuring of his exposur...
Avecho seeks ASX quotation for nearly 150m new shares
May 13, 2026
Avecho Biotechnology Limited has applied to the ASX for quotation of 149,983,861 new ordinary fully paid shares following recent security issuances. The application covers two tranches, with 3,316,013 shares issued on 8 May 2026 and 146,667,848 sh...
Avecho lifts cash and streamlines capital ahead of pivotal CBD insomnia trial milestone
May 12, 2026
Avecho Biotechnology has boosted its balance sheet with approximately $1.9 million from the exercise of listed AVEOA options before their expiry, taking pro forma cash to about $6.3 million as at 31 March 2026 and lifting shares on issue to 3.83 b...
Avecho Seeks ASX Quotation for Newly Issued Shares
May 7, 2026
Avecho Biotechnology Limited has applied to the ASX for quotation of new ordinary fully paid shares following the issue of additional securities. The company will have 1,807,146 new shares quoted from 4 May 2026 and a further 5,193,571 shares quot...
Avecho appoints new company secretary to strengthen ASX governance
May 1, 2026
Avecho Biotechnology has appointed experienced corporate lawyer and company secretary Naomi Lawrie as its new Company Secretary, effective 1 May 2026, following internal team changes at its corporate services provider Vistra Australia. Lawrie, who...
Avecho Flags Imminent Option Expiry as It Advances CBD Insomnia Trial
Apr 29, 2026
Avecho Biotechnology has notified holders of its listed options (ASX: AVEOA) that the options, exercisable at $0.012, will expire at 5:00pm AEST on 10 May 2026, with trading to cease on 4 May 2026. Option holders may choose to exercise all or part...
Avecho Exceeds Phase III Insomnia Trial Target as Key Interim Read-Out Nears
Apr 28, 2026
Avecho Biotechnology has surpassed its recruitment target for the interim analysis of its pivotal Phase III trial of a TPM-enhanced CBD soft-gel capsule for insomnia, randomising 244 patients, 16% above plan, to strengthen statistical power. The m...
Avecho sets 2026 AGM date and shifts to digital meeting materials
Apr 23, 2026
Avecho Biotechnology Limited has scheduled its Annual General Meeting for Tuesday, 26 May 2026 at 1:00pm AEST, to be held at Grant Thornton’s offices in Collins Square, Melbourne. Shareholders are encouraged to participate either in person o...
Avecho to Showcase CBD Insomnia Program at NWR Healthcare Conference
Mar 23, 2026
Avecho Biotechnology will present at the NWR Virtual Healthcare Conference on 25 March 2026, with CEO Dr Paul Gavin outlining the company’s progress and making the session accessible to investors via live stream and subsequent online replay....
Avecho hits key Phase III recruitment milestone in CBD insomnia trial
Mar 1, 2026
Avecho Biotechnology has completed recruitment of roughly 210 patients for the interim analysis cohort of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia, with results expected in June 2026. The study is intended to ...
Avecho Files Updated Corporate Governance Statement and Appendix 4G with ASX
Feb 27, 2026
Avecho Biotechnology Limited has lodged its Corporate Governance Statement for the financial year ended 31 December 2025, confirming that the document is current as of 27 February 2026 and has been approved by the board. The statement, accessible ...
Avecho Widens Annual Loss Despite Higher Revenue as Development Spending Continues
Feb 27, 2026
Avecho Biotechnology Limited has reported a 9.3% increase in revenues from ordinary activities to $1.24 million for the year ended 31 December 2025, while its net tangible assets per ordinary security declined to 0.04 cents from 0.10 cents. The co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.